Ai-BrainScience Inc (Head Office: Osaka, CEO: Kentaro Takamura Ph.D., “the company/we” hereof) is pleased to announce that its product, AiBS-01, has received premarket approval as a Software as a Medical Device (SaMD) from the Ministry of Health, Medical Device Authority in Malaysia, following its approval in Indonesia.
We are actively expanding our business and plan to launch AiBS-01 in the Asian market. This approval makes Malaysia the third country, after Japan and Indonesia, to approve AiBS-01. Moving forward, we will establish a sales infrastructure in preparation for the product launch, including collaboration with distribution partners.
Overview of AiBS-01
AiBS-01 is a Software as a Medical Device (SaMD) designed for use with the Apple iPad. It provides a 3-minute automatic assessment based on the patientʼs gaze patterns on the screen. This approach eliminates the need for reliance on the physicianʼs expertise, enabling a more objective and quantitative evaluation.
Cognitive function tests, both domestically and internationally, often rely on screening methods such as the MMSE (Mini-Mental State Examination), which typically require around 20 minutes to administer*1. These tests also demand specialized knowledge and experience from the examiner and can impose significant psychological burden on the examinee. It has been reported that approximately 70% of examinees experience distress during the testing process*2. As a result, there is a growing demand for simpler, more objective methods of assessment. We hope that AiBS-01 will expand the options available for cognitive testing, helping to address current challenges both in Japan and abroad, and contributing to the early detection of dementia.
Country of approval for AiBS-01(As of 18 November 2024)
Approval Date | Distributor | ||
1 | Japan (Brand Name:MIREVOⓇ) | October 2023 | Otsuka Pharmaceutical Inc. |
2 | Indonesia | August 2024 | TBD |
3 | Malaysia | October 2024 | TBD |
*1: Haubois et al. BMC Geriatrics 2011, 11:59
*2: Self-Reported Distress After Cognitive Testing In Patients With Alzheimer’s Disease, August 2008
<Contact>
Ai-BrainScience Inc.
TEL:+81-3-6272-6744
e-Mail:info@ai-brainscience.co.jp
URL:https://www.ai-brainscience.co.jp/en/